Hostname: page-component-7c8c6479df-fqc5m Total loading time: 0 Render date: 2024-03-28T20:54:19.166Z Has data issue: false hasContentIssue false

Azoman (Triazol 156) As a Convulsant

Published online by Cambridge University Press:  08 February 2018

F. J. Napier*
Affiliation:
Carlton Hayes Hospital, Narborough, Leicester

Extract

Since Meduna in 1934 introduced the treatment of schizophrenic states by induced epileptiform convulsions, a volume of literature has appeared on the use of cardiazol as convulsant. But although cardiazol proved immensely superior to the original camphor, it is not without some serious disadvantages. These led naturally to the search for further improvement in the convulsant agent, and it is with one of the successors to cardiazol, introduced by Walk and Mayer-Gross (1938), and known as azoman or triazol 156, that this record is concerned.

Type
Clinical Note
Copyright
Copyright © Royal College of Psychiatrists, 1939 

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

References

Walk, A., and Mayer-Gross, W.Lancet, 1938, i, p. 1324; Journ. Ment. Sci., 1938, lxxiv, p. 637.Google Scholar
McGuinness, J. P.Lancet, 1939, i, p. 508.CrossRefGoogle Scholar
Stalker, H.Ibid., 1938, ii, p. 1172.Google Scholar
Submit a response

eLetters

No eLetters have been published for this article.